For: | Sukeepaisarnjaroen W, Pham T, Tanwandee T, Nazareth S, Galhenage S, Mollison L, Totten L, Wigg A, Altus R, Colman A, Morales B, Mason S, Jones T, Leembruggen N, Fragomelli V, Sendall C, Guan R, Sutedja D, Tan SS, Dan YY, Lee YM, Luman W, Teo EK, Than YM, Piratvisuth T, Lim SG. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers. World J Gastroenterol 2015; 21(28): 8660-8669 [PMID: 26229408 DOI: 10.3748/wjg.v21.i28.8660] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i28/8660.htm |
Number | Citing Articles |
1 |
Angeline Oi‐Shan Lo, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong. Cost‐effectiveness of the highly effective direct‐acting antivirals in the treatment of chronic hepatitis C in Hong Kong. Journal of Gastroenterology and Hepatology 2017; 32(5): 1071 doi: 10.1111/jgh.13638
|
2 |
Emma Gray, Suzanne Norris, Susanne Schmitz, Aisling O'Leary. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. Journal of Comparative Effectiveness Research 2017; 6(1): 65 doi: 10.2217/cer-2016-0042
|
3 |
Yock Young Dan, Seng Gee Lim. Hepatitis C: An Eastern Perspective. Gastroenterology Clinics of North America 2015; 44(4): 793 doi: 10.1016/j.gtc.2015.07.007
|
4 |
Ying Jiao Zhao, Ai Leng Khoo, Liang Lin, Monica Teng, Calvin J Koh, Seng Gee Lim, Boon Peng Lim, Yock Young Dan. Cost‐effectiveness of strategy‐based approach to treatment of genotype 1 chronic hepatitis C. Journal of Gastroenterology and Hepatology 2016; 31(9): 1628 doi: 10.1111/jgh.13341
|